Medical Cannabis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

B2B is the fastest growing sector, North America is the largest market

The Global Medical Cannabis Market is anticipated to experience substantial growth, expanding from USD 28.81 Billion in 2025 to USD 90.82 Billion by 2031 at a CAGR of 21.09%. This market involves the therapeutic use of the Cannabis sativa plant and its cannabinoid derivatives, such as THC and CBD, for medical conditions under professional oversight. Its expansion is driven primarily by increasing global legislative approval of medical cannabis, the rising prevalence of chronic diseases necessitating long-term pain management, and a growing geriatric population. The significant international trade volume and rapid scalability of the sector are evident, for instance, in Germany's import of nearly 57 tons of medical cannabis products in the third quarter of 2025.

Market Drivers

The primary force reshaping the medical cannabis landscape is the expanding global legalization and regulatory approvals, as governments increasingly dismantle prohibitionist policies to create structured access systems. This legislative shift not only legitimizes the sector but also establishes secure avenues for physicians to prescribe cannabinoid-based medicines, thereby rapidly increasing patient enrollment in regulated systems.

Examples include Australia's approval of over 113,000 Special Access Scheme applications in the first half of 2025, a 27% year-over-year increase, and Florida's medical marijuana registry exceeding 930,000 active patients by October 2025. Furthermore, the rising prevalence of chronic diseases and growing clinical evidence supporting cannabinoid efficacy for conditions like epilepsy, multiple sclerosis, and chronic pain, coupled with the urgent need for palliative care alternatives for the expanding geriatric population, further accelerate market momentum. This demand is commercially validated by the success of clinically proven cannabinoid-derived medications, such as Jazz Pharmaceuticals' Epidiolex, which generated $972.4 million in net product sales in 2024.

Market Challenges

A significant impediment to the global medical cannabis sector's scalability is the absence of harmonized regulatory frameworks across nations. Unlike the standardized international protocols governing traditional pharmaceuticals, cannabis products are subject to disparate national laws concerning Good Manufacturing Practices, labeling standards, and permissible cannabinoid concentrations. This regulatory fragmentation forces exporters to navigate unique and complex compliance regimes for each destination country, substantially increasing operational costs and delaying market entry.

Consequently, companies may avoid emerging markets where compliance burdens outweigh potential revenue, leading to a concentration of supply in fewer jurisdictions rather than broad global expansion. This regulatory inconsistency also hinders growth by channeling trade into specific bilateral corridors instead of enabling a fluid global market, diverting resources from innovation and research due as manufacturers focus on administrative requirements. Canadian medical cannabis exports, for instance, reached CAD 218 million in 2024, demonstrating producers' prioritization of a limited number of aligned international markets.

Market Trends

A crucial market trend is the shift toward EU-GMP and pharmaceutical-grade product standardization, as producers increasingly prioritize stringent international quality protocols to access lucrative export markets. Leading companies are reconfiguring their operations to meet Good Manufacturing Practice (GMP) standards, particularly those required by major importers like Germany, enabling them to penetrate federally regulated jurisdictions and bypass saturated domestic markets.

This strategic focus ensures product consistency and compliance, essential for integration into European and Oceanian medical supply chains, as highlighted by Aurora Cannabis' international medical cannabis net revenue more than doubling to represent 61% of its global medical cannabis revenue in Fiscal 2025 Fourth Quarter. Concurrently, the industry is witnessing an expansion of clinical trials dedicated to disease-specific therapeutic indications, signifying a transition from general wellness claims to evidence-based pharmaceutical development. Market participants are allocating substantial capital to rigorous testing to obtain regulatory approval for precise conditions, such as epilepsy or cancer-related cachexia, thereby building a competitive advantage based on intellectual property and proven efficacy. This aligns the industry with traditional biotechnology models, where value is derived from successful clinical outcomes, exemplified by Jazz Pharmaceuticals' research and development expenses reaching $809.3 million in 2024 for advancing cannabinoid-based therapies.

Key Market Players

• Canopy Growth Corporation.
• Aphria, Inc.
• Maricann Group, Inc.
• Tikun Olam - Cannabit Pharmaceuticals Ltd.
• MedReleaf Corporation
• GW Pharmaceuticals plc.
• Cannabis Sativa, Inc.
• Medical Marijuana, Inc.
• Aurora Marijuana Inc.
• Cronos Group Inc

Report Scope

In this report, the Global Medical Cannabis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Medical Cannabis Market, by Product Type:

• Buds/Marijuana Flower
• Cannabis Extracts

Medical Cannabis Market, by Active Ingredient:

• Tetrahydrocannabinol (THC)
• Cannabidiol (CBD)
• Others

Medical Cannabis Market, by Distribution Channel:

• B2B
• B2C

Medical Cannabis Market, by Application:

• Chronic Pain
• Mental Disorders
• Cancer
• Epilepsy
• Others

Medical Cannabis Market, by End User Industry:

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutions
• Others

Medical Cannabis Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Medical Cannabis Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.